TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02891668

Intervention type: DRUG
Intervention: Levothyroxine treatment
Description: Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
Study: NCT00134901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01630070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable drug eluting stent
Description: Self-Expanding Paclitaxel-Eluting stent
Study: NCT03170063

Intervention type: PROCEDURE
Intervention: Procedure/Surgery: Biofluid samplings
Description: Biofluid samplings (blood and cerebrospinal fluid (CSF))

Intervention type: PROCEDURE
Intervention: Procedure/Surgery: Biofluid samplings
Description: Biofluid samplings (blood and cerebrospinal fluid (CSF))
Study: NCT02125864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: collecting blood samples
Study: NCT02624180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance containing no medication
Study: NCT04735978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified HSV-1
Study: NCT04167852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message
Description: Patients will receive a daily text message stating how many days they have until or since their surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message
Description: Patients will receive a daily text message stating how many days they have until or since their surgery.
Study: NCT04735978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD1 monoclonal antibody
Study: NCT00753311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan or placebo
Description: Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rizatriptan or placebo
Description: Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
Study: NCT03169231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered
Study: NCT04167852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Patients will receive a link to mindfulness meditation intervention for ten minutes.
Study: NCT03401099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of CTI
Description: Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon PVI
Description: Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
Study: NCT01945086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injections of placebo at Week 0 and Week 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concomitant topical medications for atopic dermatitis
Description: Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant topical medications for atopic dermatitis
Description: Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant topical medications for atopic dermatitis
Description: Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
Study: NCT01381198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal rectus femoris transfer
Description: Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
Study: NCT04472715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: follicular unit extarcation and platelet rich plasma
Description: hair transplantation procedure
Study: NCT00295932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study: NCT03948919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota
Description: Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
Study: NCT03948919

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
Study: NCT00996060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort -1
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day.
Study: NCT01653392

Intervention type: BIOLOGICAL
Intervention: Observational Intervention
Description: This is an observational study, therefore no interventions are specified.
Study: NCT00943371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6349
Description: Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MK6349
Description: Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
Study: NCT00996060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 0
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort.
Study: NCT03941977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous introduction of cannula
Description: An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Grafting
Description: A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
Study: NCT01754389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT03070301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 200 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 5 mg daily or 2.5mg daily
Study: NCT00006229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Study: NCT03223129

Intervention type: OTHER
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
Study: NCT03169231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered
Study: NCT03223129

Intervention type: OTHER
Group type: OTHER
Intervention: Graded intravenous glucose infusion
Description: Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.

Intervention type: OTHER
Group type: OTHER
Intervention: Graded intravenous glucose infusion
Description: Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.

Intervention type: OTHER
Group type: OTHER
Intervention: Graded intravenous glucose infusion
Description: Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
Study: NCT03011164

Intervention type: PROCEDURE
Intervention: Walk and Run
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Walk and Run
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Walk and Run
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Walk and Run
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
Study: NCT03169231

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously delivered
Study: NCT03608397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Study: NCT00996060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 1
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 2
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 3
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 4
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort 5
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day.
Study: NCT03045341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB medication (Naltrexone Bupropion combination)
Description: NB medication
Study: NCT03608397

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study: NCT02051712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: individualized exercise training
Study: NCT01160159

Intervention type: OTHER
Intervention: Tests
Description: Arterial parameters

Intervention type: OTHER
Intervention: Healthy volunteers
Description: Arterial parameters and blood test
Study: NCT03734432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGAR-Breast TeleOp
Description: Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
Study: NCT01444690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimiracetam
Description: Capsules for oral administration twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimiracetam 25 mg
Description: Inactive dose level in capsules administered orally twice daily
Study: NCT01747109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREOXYFLOW
Description: Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD FACE MASK
Description: Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)
Study: NCT00658632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Study: NCT02412540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Intervention
Description: Dietary, behavioral and activity interventions designed to reduce weight.
Study: NCT02976363

Intervention type: RADIATION
Intervention: Radiotherapy breast cancer

Intervention type: OTHER
Intervention: Evaluation Maximal Respiratory Pressures

Intervention type: OTHER
Intervention: Evaluation Maximal Respiratory Pressures
Study: NCT04615611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: inhalation of salbutamol
Study: NCT02860702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Derived Fortifier
Description: Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human/Bovine Milk
Description: Bovine milk derived fortification
Study: NCT04128956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
Study: NCT03983642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii balance board
Description: Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level.
Study: NCT03045341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB medication (Naltrexone Bupropion combination)
Description: NB medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) counseling
Description: BWL counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) counseling
Description: BWL counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02654938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilan (M-VM3)
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% infusion solution of dextrose
Study: NCT00141115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Levetiracetam 1500 mg BID
Study: NCT03259815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: P.I.O.S.
Description: Physiologically-Guided Incremental Optimisation Strategy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre and post-PCI coronary physiology measurements
Description: Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre and post-PCI coronary physiology measurements
Description: Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
Study: NCT01416480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theobromine 300mg
Description: Capsule, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodropropizine 10mg
Description: Syrup, t.i.d.
Study: NCT01567995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasone Butyrate 0.05% Cream
Description: Clobetasone Butyrate 0.05% Cream

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle (base cream)
Description: Vehicle (base cream)